|Videos|July 15, 2021
Incorporating Esketamine into Practice for Treatment-Resistant Depression
Advertisement
Episodes in this series
Requirements that healthcare clinics must satisfy to become a certified treatment center permitted to administer intranasal esketamine to patients with treatment-resistant depression.
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Overlooking how hearing loss and sign language shape the Mental Status Examination can make language deprivation look like psychosis, authors warn.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Explore Q3 2026 psych pipeline highlights—wins, setbacks, top disorders, and breakthrough ADHD, TRD, schizophrenia and Alzheimer therapies to watch.
Advertisement
Advertisement
Trending on Psychiatric Times
1
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
2
The Psychiatric Pipeline in Review: Quarter 3, 2026
3
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
4
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
5